Skip to main content

Table 3 Results from BioBERT_directionalDDI applied to all human prescription drug labels from the NIH

From: Deep learning-enabled natural language processing to identify directional pharmacokinetic drug–drug interactions

Drug

Total sentences

PK DDI sentences

Object sentences (Unique sentences)

Vandetanib

Example Sentence

923

132

16 (4)

The coadministration of rifampicin with CAPRELSA decreased the geometric mean AUC0-504h of vandetanib by 40% (90% confidence interval (CI) 56%, 63%) compared to vandetanib alone

Sotalol

Example Sentence

16,658

121

42 (9)

Telithromycin has been shown to decrease the Cmax and AUC of sotalol by 34% and 20%, respectively, due to decreased absorption

Quinidine

Example Sentence

31,266

7682

1583 (118)

Diltiazem significantly increases the AUC of quinidine by 51%, T1/2 by 36%, and decreases its CL by 33%

Ibutilide

688

0

0 (0)

Dofetilide

Example Sentence

8346

645

601 (60)

Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%

Disopyramide

Example Sentence

6087

101

49 (12)

In vitro metabolic studies indicated that disopyramide is metabolized by cytochrome P450 3A4 and that inhibitors of this enzyme may result in elevation of plasma levels of disopyramide

Bepridil

149

0

0 (0)

Azimilide

0

0

0 (0)

Terfenadine

Example Sentence

6135

1098

629 (29)

In a drug interaction study in 16 healthy volunteers, co-administration of multiple doses of terfenadine (60 mg every 12 h) and ZYFLO (600 mg every 6 h) for 7 days resulted in a decrease in clearance of terfenadine by 22% leading to a statistically significant increase in mean AUC and Cmax of terfenadine of approximately 35%

Risperidone

Example Sentence

68,070

3783

2250 (188)

Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC

Pimozide

Example Sentence

13,493

2647

1818 (136)

In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) coadministration to steady state was associated with a mean increase in pimozide AUC and Cmax of about 40%, but was not associated with any changes in EKG

Ondansetron

Example Sentence

77,681

2511

1234 (24)

In a pharmacokinetic study of 10 healthy subjects receiving a single-dose intravenous dose of ondansetron 8 mg after 600 mg rifampin once daily for five days, the AUC and the t1/2 of ondansetron were reduced by 48% and 46%, respectively

Droperidol

1939

16

0 (0)

Domperidone

0

0

0 (0)

Clozapine

Example Sentence

16,343

2774

1773 (118)

Following concomitant administration of 250 mg CIPRO with 304 mg clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively

Clarithromycin

Example Sentence

90,366

10,775

2464 (176)

Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state clarithromycin Cmin and AUC of 33% and 18%, respectively

Cisapride

Example Sentence

6433

1167

1001 (51)

Following a single dose of fluconazole, there was a 101% increase in the cisapride AUC and a 91% increase in the cisapride Cmax

Chlorpromazine

12,207

1103

101 (0)

Astemizole

Example Sentence

2431

250

244 (15)

Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole

Verapamil

Example Sentence

43,977

7691

1504 (73)

The AUC and Cmax for both verapamil and norverapamil are increased when 240 mg of controlled release verapamil is

administered concomitantly with 4 mg trandolapril

Tamoxifen

Example Sentence

27,560

961

401 (41)

Data from a clinical trial in patients with breast cancer indicated that tamoxifen Cmax and AUC increased approximately twofold following coadministration of 600 mg ribociclib

Ranolazine

Example Sentence

11,979

1932

620 (100)

Plasma levels of ranolazine with RANEXA 1000 mg twice daily are increased by 50 to 130% by diltiazem 180 to 360 mg, respectively

Nitrendipine

190

0

0 (0)

Nifedipine

Example Sentence

40,859

6850

3714 (177)

The mean values of Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol

Mexiletine

Example Sentence

5359

725

252 (20)

In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the

coadministration of fluvoxamine, an inhibitor of CYP1A2

Metoprolol

Example Sentence

67,595

3986

2790 (152)

Administration of 20 mg/day Lexapro for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg)

Loratadine

Example Sentence

5875

436

194 (14)

Loratadine, a non-sedating antihistaminic, is metabolized primarily by CYP3A and its metabolism can be inhibited by amiodarone

Diltiazem

Example Sentence

45,605

10,797

1830 (96)

A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of cimetidine at 1200 mg per day and a single dose of diltiazem 60 mg

  1. The first column indicates the drug of interest. The second column (total sentences) shows the total number of sentences that the drug of interest appears in. The third column (PK DDI sentences) shows the number of sentences where the drug appears that also contain some PK DDI information. The fourth column (object sentences) shows the total number of sentences where the drug of interest appears as the object in the PK DDI. There is a, potentially large, number of repeated sentences for each drug across all the drug labels so the number in parentheses in this column indicates the number of unique sentences. Of note two of the reference drugs, azimilide and domperidone, did not have any sentences mentioning their names probably because they were not approved in the USA. And for some other drugs, such as bepridil, that were mentioned in sentences in their own labels or other drugs’ labels, however none of these sentences contain PK DDI. Where possible, the second row for a drug shows an example sentence identified by the model. Most of these example sentences have quantitative information that can help to facilitate the determination of the high clinical exposure of the reference drug